Glycogen synthase kinase3 and prostate cancer: An update.
- Author:
Qing-Ting HU
1
;
Chang-Bai LIU
1
;
Ben-Yi LI
1
Author Information
1. Research Institute of Cell Therapy, People's Hospital of Three Gorges University, Yichang, Hubei 443000, China.
- Publication Type:Journal Article
- Keywords:
prostate cancer;
cancer treatment;
glycogen synthase kinase-3
- MeSH:
Androgens;
Animals;
Cell Line, Tumor;
Glycogen Synthase Kinase 3;
antagonists & inhibitors;
metabolism;
Glycogen Synthase Kinase 3 beta;
antagonists & inhibitors;
metabolism;
Humans;
Male;
Neoplasm Proteins;
metabolism;
Neoplasms, Hormone-Dependent;
enzymology;
metabolism;
Prostatic Neoplasms;
drug therapy;
enzymology;
pathology;
Receptors, Androgen;
metabolism
- From:
National Journal of Andrology
2017;23(2):178-182
- CountryChina
- Language:Chinese
-
Abstract:
Glycogen synthase kinase3 (GSK3α and GSK3β) are serine/threonine protein kinases acting on numerous substrates and involved in the regulation of various cellular functions such as their proliferation, survival, glycogen metabolism, and autophagy. Accumulating evidence indicates that the expression of GSK3α is increased mainly in androgendependent while that of GSK3β in androgenindependent prostate cancer, and that GSK3β is also involved in the regulation of the transactivation of the androgen receptor (AR) and growth of prostate cancer. Animal experiments have proved that some GSK3 inhibitors, such as lithium, can significantly suppress tumor growth in different animal models of prostate cancer. The GSK3 inhibitor is promising to be an important agent for the clinical management of prostate cancer.
